Form 4: Amgen Director Charles M. Holley Reports Acquisition of Common Stock

Director Charles M. Holley reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Summary

• Charles M. Holley, a director at Amgen Inc., filed a Form 4 detailing changes in beneficial ownership.
• On November 4, 2024, Holley acquired 268.215 shares of Amgen common stock through the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted under the Amgen Inc. 2009 Director Incentive Program and vested immediately.
• The reported transaction resulted in Holley directly owning 10,114.0229 shares of Amgen common stock.
• Holley also indirectly owns 1,260 shares through the Holley Family Trust.
• The shares include 1,052 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it simply reports a transaction. The acquisition of shares by a director is generally viewed as a slightly positive sign.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies like Amgen. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for directors and officers of publicly traded companies, ensuring transparency in their trading activities.
• The Amgen Inc. 2009 Director Incentive Program is similar to equity compensation plans offered by other large pharmaceutical companies to align director interests with shareholder value.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.

Key Dates